Last updated: February 1, 2026
Case No.: 1:17-cv-01696
Court: United States District Court for the District of Delaware
Filing Date: August 23, 2017
Parties:
- Plaintiff: Shire Development LLC
- Defendant: Teva Pharmaceuticals USA, Inc.
Executive Summary
Shire Development LLC (“Shire”) filed a patent infringement lawsuit against Teva Pharmaceuticals USA, Inc. (“Teva”) alleging that Teva’s proposed generic version of Shire's Vyvanse® (lisdexamfetamine dimesylate) infringes on Shire’s patents. The case highlights key issues surrounding patent validity, infringement, and the Hatch-Waxman Act’s implications in generic drug approval processes. As of the latest filings, the case remains active, with the court scrutinizing patent scope, validity, and Teva’s potential to launch a generic product.
Case Overview & Chronology
| Key Events |
Dates |
Details |
| Filing |
August 23, 2017 |
Shire files complaint in the U.S. District Court for the District of Delaware alleging patent infringement. |
| Patent Asserted |
U.S. Patent No. 8,502,143 |
Covering specific formulations and methods related to Vyvanse® (lisdexamfetamine dimesylate). |
| Preliminary Motions |
2018–2019 |
Teva seeks to dismiss or challenge patent validity; motions to stay proceedings pending Patent Office review. |
| District Court Proceedings |
2018–2021 |
Discovery phase; expert disclosures; infringement and validity analyses. |
| Patent Office Proceedings |
Ongoing |
Inter partes reviews and reexaminations potentially challenge patent claims. |
| Current Status |
2023 |
Litigation ongoing; no final judgment; settlement discussions reported but unconfirmed. |
Legal Claims and Defenses
1. Patent Infringement Allegations
Shire alleges Teva’s proposed generic infringes on the ‘143 patent by providing a bioequivalent formulation. The patent claims cover components related to the delayed-release properties of lisdexamfetamine formulations.
2. Patent Validity Challenges
Teva contests patent validity based on grounds including:
- Obviousness under 35 U.S.C. § 103
- Lack of novelty under 35 U.S.C. § 102
- Lack of written description and enablement under 35 U.S.C. § 112
3. Invalidity Defenses
- Prior art references that allegedly anticipate or render claims obvious.
- Arguments that the patent claim scope is overly broad or indefinite.
4. Hatch-Waxman Act Implications
The case revolves around the Orange Book listing of the patent, and whether Teva's Abbreviated New Drug Application (ANDA) label infringes or avoids infringement through safe harbor provisions.
Patent and Regulatory Environment
| Legal Framework |
Relevant Statutes |
Key Policies |
Implications |
| Patent Law |
Title 35 U.S.C. |
Patent term extensions and exclusivity periods |
Validity and infringement issues determine market exclusivity periods. |
| Hatch-Waxman |
21 U.S.C. §§ 355, 356 |
Statutory pathway for generic approval |
Balances patent rights with generic entry via Paragraph IV certifications. |
| FDA Regulations |
21 CFR Part 314 |
ANDA requirements and drug approval standards |
Determines what generic must demonstrate to gain approval. |
Technical and Scientific Dissection
1. Patent Claims Summary
| Claim Type |
Scope |
Focus |
| Composition |
Specific ratios and forms of lysdexamfetamine |
Controlled-release formulations or salts |
| Method of Treatment |
Dosage regimes, administration methods |
Controlled release and timing |
2. Technical Disputes
- Whether the asserted patent enables the manufacture of generic equivalents without infringing.
- Whether Teva's proposed formulation falls within the patented scope or constitutes an infringement.
Litigation Deep-Dive: Key Legal Issues
Patent Validity and Priority
Teva’s validity defenses hinge on prior art references, including earlier formulations and filings by other companies, asserting that the patent claims are either anticipated or obvious.
Infringement Analysis
Shire claims Teva’s generic product would infringe specific claims, especially related to the delayed-release properties. Teva argues that their product uses different mechanisms or formulations that do not infringe.
Procedural Strategies
- Claims Construction: The court must interpret patent claims before ruling on infringement or validity.
- Motions to Dismiss & Summary Judgment: Teva seeks to narrow issues early.
- Inter Partes Review & Reexamination: Likely ongoing to challenge patent validity, given the high stakes for market exclusivity.
Market and Business Impact
| Industry Impact |
Impact on Stakeholders |
Timing and Patent Life |
| Patent protections delay generic competition |
Shire maintains market share, premium pricing |
Patent expiration around 2024–2025 if upheld |
| Off-label or invalid patents can open market access earlier |
Teva’s market entry risks legal challenges |
Possible extension via patent litigation outcomes |
| Regulatory pathways influence patent strategies |
Generic manufacturers analyze patent landscapes |
Potential for settlement or patent challenges to influence timing |
Comparison: Patent Litigation vs. Patent Challenges in Pharmaceutical Industry
| Aspect |
Patent Litigation |
Inter Partes Review & Reexamination |
| Purpose |
Enforce patent rights or challenge infringement |
Challenge patent validity with USPTO |
| Duration |
Often longer; 2–4 years or more |
Usually 1–2 years |
| Outcome |
Court ruling; potential damages or injunction |
Patent upheld, amended, or canceled |
| Strategic Use |
Patent enforcement or defense |
Defend or weaken patent to facilitate market entry |
FAQs
Q1: What are the primary legal strategies used by Teva in this litigation?
A: Teva primarily challenges patent validity through arguments of obviousness and anticipation, while also examining claim construction to dispute infringement.
Q2: How does the Hatch-Waxman Act influence this case?
A: The Act’s provisions allow Teva to file an ANDA with a Paragraph IV certification, asserting that patent claims are invalid or not infringed, effectively initiating patent challenge procedures and potentially triggering patent damages or stay periods.
Q3: What are typical outcomes in patent infringement suits involving generic drugs?
A: Possible resolutions include patent validity confirmation, injunctions against generics, settlements permitting delayed generic market entry, or invalidation of patents via USPTO proceedings.
Q4: What impact does patent invalidation have on the pharmaceutical market?
A: Invalidating patents can enable faster market entry, leading to lower prices and increased generic competition, which can significantly erode brand-market share.
Q5: How do FDA regulations intersect with patent rights in this litigation?
A: FDA approves generic entry based on ANDA filings, but patent rights must be resolved beforehand, either through litigation or patent challenge procedures, before marketing a generic.
Key Takeaways
- The case underscores the complex interplay between patent law, FDA regulatory processes, and market competition.
- Validity challenges based on prior art and obviousness are central, with Teva actively seeking to invalidate the ‘143 patent.
- Patent scope interpretation and claim construction are critical to establishing infringement.
- Ongoing USPTO proceedings (inter partes reviews) could significantly influence the case's outcome.
- The outcome impacts market dynamics for lisdexamfetamine formulations and can set precedents for future patent litigation strategies.
References
- United States District Court, District of Delaware. Case No.: 1:17-cv-01696.
- Patent No. 8,502,143. U.S. Patent and Trademark Office.
- Hatch-Waxman Act, 21 U.S.C. §§ 355, 356.
- FDA. 21 CFR Part 314.
- Industry reports and case law on patent litigation in pharmaceuticals.
Note: This summary reflects publicly available information and the latest case status as of Q1 2023. Future developments may alter case outcomes or strategies.
